BioMarinâs achondroplasia drug gets nod for children of all ages
HQ Team October 21, 2023: The FDA cleared BioMarin Pharmaceuticalsâs Voxzogo injection for treating achondroplasia, a common form of short-limbed dwarfism in children.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team October 21, 2023: The FDA cleared BioMarin Pharmaceuticalsâs Voxzogo injection for treating achondroplasia, a common form of short-limbed dwarfism in children.
HQ Team September 2, 2023: A panel of the European Unionâs health regulator, the European Medicines Agency, has warned against the use of.